SherrardD.J., HerczG., PeiY., MaloneyN.A., GreenwoodC., ManuelA.The spectrum of bone disease in end-stage renal failure—an evolving disorder.Kidney Int1993; 43(2): 436–42.
2.
QiQ., Monier–FaugereM.C., GengZ., MallucheH.H.Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.Am J Kidney Dis, 1995. 26(4): 622–31.
3.
CouttenyeM.M., D'HaeseP.C., DengJ.T., Van HoofV.O., VerpootenG.A., De BroeM.E.High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population.Nephrol Dial Transplant1997; 12(10): 2144–50.
4.
SherrardD., BaylinkD., WergedalJ.Bone disease in uremia.Trans Am Soc Artif Intern Organs1972; 18(0): 412–15, 421.
MassryS.G., SmogorzewskiM.Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia.Semin Nephrol1994; 14(3): 219–31.
7.
HsuC.H.Are we mismanaging calcium and phosphate metabolism in renal failure?Am J Kidney Dis1997; 29(4): 641–9.
8.
GoodmanW.G., RamirezJ.A., BelinT.R., ChonY., GalesB., SegreG.V.Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.Kidney Int1994; 46(4): 1160–6.
9.
PeiY., HerczG., GreenwoodC., SegreG., ManuelA., SaiphooC.Risk factors for renal osteodystrophy: a multivariant analysis.J Bone Miner Res1995; 10(1): 149–56.
10.
CocoM., RushH.Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.Am J Kidney Dis2000; 36(6): 1115–21.
11.
AtsumiK., KushidaK., YamazakiK., ShimizuS., OhmuraA., InoueT.Risk factors for vertebral fractures in renal osteodystrophy.Am J Kidney Dis1999; 33(2): 287–93.
12.
KurzP., Monier–FaugereM.C., BognarB., WernerE., RothP., VlachojannisJ.Evidence for abnormal calcium homeostasis in patients with adynamic bone disease.Kidney Int1994; 46(3): 855–61.
13.
WangM., HerczG., SherrardD.J., MaloneyN.A., SegreG.V., PeiY.Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.Am J Kidney Dis1995; 26(5): 836–44.
14.
SlatopolskyE., FinchJ., ClayP., MartinD., SicardG., SingerG.A novel mechanism for skeletal resistance in uremia.Kidney Int2000; 58(2): 753–61.
15.
JohnM.R., GoodmanW.G., GaoP., CantorT.L., SaluskyI.B., JuppnerH.A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.J Clin Endocrinol Metab1999; 84(11): 4287–90.
16.
Monier–FaugereM.C., GengZ., MawadH., FriedlerR.M., GaoP., CantorT.L.Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.Kidney Int2001; 60: 1460–8.
17.
DelmezJ.A.Avoiding renal osteodystrophy in peritoneal dialysis patients.Semin Dial1995; 8: 373–7.
18.
MaungH.M., ElangovanL., FrazaoJ.M., BowerJ.D., KelleyB.J., AcchiardoS.R.Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.Am J Kidney Dis2001; 37(3): 532–43.
19.
MartinK.J., GonzalezE.A., GellensM., HammL.L., AbboudH., LindbergJ.19–Nor-1–α-25–dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.J Am Soc Nephrol1998; 9(8): 1427–32.
20.
SheikhM.S., MaguireJ.A., EmmettM., Santa AnaC.A., NicarM.J., SchillerL.R.Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.J Clin Invest1989; 83(1): 66–73.
21.
BraunJ., OldendorfM., MoshageW., HeidlerR., ZeitlerE., LuftF.C.Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients.Am J Kidney Dis1996; 27(3): 394–401.
MeemaH.E., OreopoulosD.G., RapoportA.Serum magnesium level and arterial calcification in end-stage renal disease.Kidney Int1987; 32(3): 388–94.
24.
CassidyM.J., OwenJ.P., EllisH.A., DewarJ., RobinsonC.J., WilkinsonR.Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis.Q J Med1985; 54(213): 29–48.
25.
ParfittA.M.Soft-tissue calcification in uremia.Arch Intern Med1969; 124(5): 544–56.
26.
ShearM., KramerB.Composition of bone. III. Physicochemical mechanism.J Biol Chem1928; 79: 125–45.
27.
HerbertF., MillerH., RichardsonG.Chronic renal disease, secondary parathyroid hyperplasia, decalcification of bone and metastatic calcification.J Pathol Bacteriol1941; LIII(2): 161–83.
28.
GoodmanW.G., GoldinJ., KuizonB.D., YoonC., GalesB., SiderD.Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.N Engl J Med2000; 342(20): 1478–83.
29.
AhmedS., O'NeillK.D., HoodA.F., EvanA.P., MoeS.M.Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells.Am J Kidney Dis2001; 37(6): 1267–76.
30.
MarchaisS.J., MetivierF., GuerinA.P., LondonG.M.Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease.Nephrol Dial Transplant1999; 14(9): 2178–83.
31.
NarangR., RidoutD., NonisC., KoonerJ.S.Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease.Int J Cardiol1997; 60(1): 73–9.
BlockG.A., Hulbert–ShearonT.E., LevinN W., PortF.K.Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.Am J Kidney Dis1998; 31(4): 607–17.
34.
LevinN.W., Hulbert–ShearonT.E., StrawdermanR.L., PortF.K.Which causes of death are related to hyperphosphatemia in hemodialysis (HD) patients? (Abstract).J Am Soc Nephrol1999; A1109.
35.
CoburnJ.W., TanA.U.Jr., LevineB.S., MazessR.B., KylloD.M., KnutsonJ.C.1 α-Hydroxy-vitamin D2: a new look at an “old” compound.Nephrol Dial Transplant1996; 11(Suppl 3): 153–7.
36.
BostromK., WatsonK.E., HornS., WorthamC., HermanI.M., DemerL.L.Bone morphogenetic protein expression in human atherosclerotic lesions.J Clin Invest1993; 91(4): 1800–9.
37.
FitzpatrickL.A., SeversonA., EdwardsW.D., IngramR.T.Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis.J Clin Invest1994; 94(4): 1597–604.
38.
ShanahanC.M., CaryN.R., MetcalfeJ.C., WeissbergP.L.High expression of genes for calcification-regulating proteins in human atherosclerotic plaques.J Clin Invest1994; 93(6): 2393–402.
39.
NakaokaT., GondaK., OgitaT., Otawara–HamamotoY., OkabeF., KiraY.Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.J Clin Invest1997; 100(11): 2824–32.
40.
ProudfootD., SkepperJ.N., ShanahanC.M., WeissbergP.L.Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression.Arterioscler Thromb Vasc Biol1998; 18(3): 379–88.
41.
ShanahanC.M., CaryN.R., SalisburyJ.R., ProudfootD., WeissbergP.L., EdmondsM.E.Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification.Circulation1999; 100(21): 2168–76.
42.
MoriK., ShioiA., JonoS., NishizawaY., MoriiH.Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells.Arterioscler Thromb Vasc Biol1999; 19(9): 2112–18.
43.
WadaT., McKeeM.D., SteitzS., GiachelliC.M.Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin.Circ Res1999; 84(2): 166–78.
BostromK.I.Cell differentiation in vascular calcification.Z Kardiol2000; 89(Suppl 2): 69–74.
46.
CanfieldA.E., AllenT.D., GrantM.E., SchorS.L., SchorA.M.Modulation of extracellular matrix biosynthesis by bovine retinal pericytes in vitro: effects of the substratum and cell density.J Cell Sci1990; 96(Pt 1): 159–69.
47.
JonoS., PeinadoC., GiachelliC.M.Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification.J Biol Chem2000; 275(26): 20197–203.
48.
MoeS.M., O'NeillK.D., DuanD., AhmedS., ChenX.N., LeapmanS.B.Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins.Kidney Int2001; [In press].
49.
LuoG., DucyP., McKeeM.D., PineroG.J., LoyerE., BehringerR.R.Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein.Nature1997; 386(6620): 78–81.
50.
BucayN., SarosiI., DunstanC.R., MoronyS., TarpleyJ., CapparelliC.Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes Dev1998; 12(9): 1260–8.
51.
HofbauerL.C., KhoslaS., DunstanC.R., LaceyD.L., BoyleW.J., RiggsB.L.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res2000; 15(1): 2–12.
52.
BoukhrisR., BeckerK.L.Calcification of the aorta and osteoporosis. A roentgenographic study.JAMA1972; 219(10): 1307–11.
53.
BanksL.M., LeesB., MacSweeneyJ.E., StevensonJ.C.Effect of degenerative spinal and aortic calcification on bone density measurements in postmenopausal women: links between osteoporosis and cardiovascular disease?Eur J Clin Invest1994; 24(12): 813–17.
54.
KielD.P., HannanM.T., CuppleL.A., WilsonP.W.F., LevyD., ClouseM.F.Low bone mineral density (BMD) is associated with coronary artery calcification.J Bone Miner Res2000; 15: 5160.
55.
HakA.E., PolsH.A., van HemertA.M., HofmanA., WittemanJ.C.Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study.Arterioscler Thromb Vasc Biol2000; 20(8): 1926–31.
56.
GarrawayW.M., StaufferR.N., KurlandL.T., O'FallonW.M.Limb fractures in a defined population. I. Frequency and distribution.Mayo Clin Proc1979; 54(11): 701–7.
57.
WexlerL., BrundageB., CrouseJ., DetranoR., FusterV., MaddahiJ.Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group.Circulation1996; 94(5): 1175–92.
58.
DrakeT.A., SchadtE., HannaniK., KaboJ.M., KrassK., ColinayoV.Genetic loci determining bone density in mice with diet-induced atherosclerosis.Physiol Genomics2001; 5(4): 205–15.
59.
FoleyR.N., ParfreyP.S., SarnakM.J.Clinical epidemiology of cardiovascular disease in chronic renal disease.Am J Kidney Dis1998; 32(5 Suppl 3): S112–19.
60.
AlemA.M., SherrardD.J., GillenD.L., WeissN.S., BeresfordS.A., HeckbertS.R.Increased risk of hip fracture among patients with end-stage renal disease.Kidney Int2000; 58(1): 396–9.
61.
Stehman–BreenC.O., SherrardD., WalkerA., SadlerR., AlemA., LindbergJ.Racial differences in bone mineral density and bone loss among end-stage renal disease patients.Am J Kidney Dis1999; 33(5): 941–6.
62.
Stehman–BreenC.O., SherrardD.J., AlemA.M., GillenD.L., HeckbertS.R., WongC.S.Risk factors for hip fracture among patients with end-stage renal disease.Kidney Int2000; 58(5): 2200–5.
63.
LarocheM., PouillesJ.M., RibotC., BendayanP., BernardJ., BoccalonH.Comparison of the bone mineral content of the lower limbs in men with ischaemic atherosclerotic disease.Clin Rheumatol1994; 13(4): 611–14.
